Thirthy-six patients with refractory anemia with excess of blasts in transformation (RAEBt), or acute myelogenous leukemia (AML) after myelodysplastic syndrome, and twenty-four patients with 'de novo' AML were treated with cytosine arabinoside (Ara-C) in low dosage. The two groups of patients were comparable with respect to age, hemoglobin level, white cell and platelet counts. Ara-C was administered subcutaneously at a dose of 10 mg/m2 every 12 hours for 21 days. Treatments were repeated every 2-3 months depending on marrow cellularity. Overall, 30% complete response and 48% partial response were observed. Neutropenia and thrombocytopenia were frequent complications. Median survival from the start of treatment was 7 months in both groups; at least 25% of patients survived more than 12 months. Survival appeared to be related to treatment response: patients achieving complete remission survived significantly longer than those who had partial remission.
LOW-DOSE CYTOSINE-ARABINOSIDE (ARA-C) THERAPY IN THE MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOGENOUS LEUKEMIA / A. MAIOLO, P. FOA, M. CORTELLARO, G. LAMBERTENGHIDELILIERS, A. COLANTONI, B. CESANA, G. CASTOLDI, M. CAZZOLA, M. GIORDANO, A. RICCARDI, E. POLLI. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 72:1(1987), pp. 61-65.
LOW-DOSE CYTOSINE-ARABINOSIDE (ARA-C) THERAPY IN THE MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOGENOUS LEUKEMIA
P. FOA;
1987
Abstract
Thirthy-six patients with refractory anemia with excess of blasts in transformation (RAEBt), or acute myelogenous leukemia (AML) after myelodysplastic syndrome, and twenty-four patients with 'de novo' AML were treated with cytosine arabinoside (Ara-C) in low dosage. The two groups of patients were comparable with respect to age, hemoglobin level, white cell and platelet counts. Ara-C was administered subcutaneously at a dose of 10 mg/m2 every 12 hours for 21 days. Treatments were repeated every 2-3 months depending on marrow cellularity. Overall, 30% complete response and 48% partial response were observed. Neutropenia and thrombocytopenia were frequent complications. Median survival from the start of treatment was 7 months in both groups; at least 25% of patients survived more than 12 months. Survival appeared to be related to treatment response: patients achieving complete remission survived significantly longer than those who had partial remission.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
